Related Experiment Video
Updated: Sep 6, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.6K
EFFECTIVENESS OF UNILATERAL ADRENALECTOMY IN BILATERAL ADRENAL INCIDENTALOMA PATIENTS WITH SUBCLINICAL
Summary
Unilateral adrenalectomy effectively treats bilateral adrenal incidentaloma with subclinical hypercortisolemia, leading to high remission rates and reduced cortisol levels. This surgical approach offers a viable alternative to bilateral adrenalectomy, minimizing long-term risks.
Area of Science:
- Endocrinology
- Surgical Oncology
Background:
- Bilateral adrenal incidentaloma (AI) presents a treatment challenge, with bilateral adrenalectomy carrying long-term risks.
- Subclinical hypercortisolemia (SH) in AI patients requires effective management strategies.
Purpose of the Study:
- To evaluate the effectiveness of unilateral adrenalectomy (UA) in treating bilateral AI patients with SH.
- To compare outcomes between patients undergoing UA and those managed conservatively.
Main Methods:
- Retrospective analysis of 35 patients with bilateral AI and SH.
- Patients were divided into UA group (n=27) and patients without adrenalectomy (PWA) group (n=8).
- Hormone levels (cortisol, ACTH) were reviewed pre- and post-treatment/follow-up, including dexamethasone suppression tests (DST).
Main Results:
- The UA group showed a 92.6% remission rate for SH, significantly lower final cortisol levels post-dexamethasone suppression (p=0.003), and higher final ACTH levels (p=0.001) compared to the PWA group.
- In the UA group, final basal cortisol (p=0.009) and post-1mg DST cortisol (p=0.004) were lower than at diagnosis.
- No patients in the PWA group recovered from hypercortisolemia during follow-up.
Conclusions:
- Unilateral adrenalectomy targeting the larger lesion is an effective treatment for bilateral AI with SH.
- UA successfully reduces excess cortisol levels and achieves high remission rates, offering an alternative to bilateral adrenalectomy.
Related Concept Videos
Adrenal Gland Disorders
1.8K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.8K
Hormones of the Adrenal Glands
2.8K
Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
2.8K
Anatomy of the Adrenal Glands
2.6K
The adrenal or supra-renal glands, situated above the kidneys and aligned with the twelfth rib, are paired pyramid-shaped structures crucial for the body's stress response. During stress, these glands secrete hormones vital for adaptive physiological reactions.
These glands possess a distinctive yellow tinge due to the stored cholesterol and fatty acids required for hormone synthesis. They are encased in a fibrous capsule and cushioned by fat.
The adrenal gland comprises two distinct...
These glands possess a distinctive yellow tinge due to the stored cholesterol and fatty acids required for hormone synthesis. They are encased in a fibrous capsule and cushioned by fat.
The adrenal gland comprises two distinct...
2.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
943
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
943
Hypothalamic-Pituitary Axis
61.5K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
61.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505

